In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Publication|Articles|August 4, 2023
Supplements and Featured Publications
- Integrated Multidisciplinary Limb Salvage Programs: Reducing Amputations Among Patients With Peripheral Artery Disease
Keck Medicine of USC and the Rancho Los Amigos National Rehabilitation Center
Advertisement
In this AJMC® Profiles in Care, key stakeholders affiliated with Keck Medicine of the University of Southern California and the Rancho Los Amigos National Rehabilitation Center in southern California share best practices for development of a limb salvage program for people with peripheral artery disease and others at high risk of limb amputation.
Articles in this issue
almost 3 years ago
Inova Health System Center of ExcellenceAdvertisement
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5